{'52WeekChange': -0.64420784,
 'SandP52WeekChange': 0.0644362,
 'address1': '10421 Pacific Center Court',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 22,
 'askSize': 1000,
 'averageDailyVolume10Day': 194462,
 'averageVolume': 351280,
 'averageVolume10days': 194462,
 'beta': 0.934719,
 'beta3Year': None,
 'bid': 19.38,
 'bidSize': 800,
 'bookValue': 14.685,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 20.41,
 'dayLow': 19.3,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.813,
 'enterpriseToRevenue': 7.281,
 'enterpriseValue': 167464496,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '858 362 6296',
 'fiftyDayAverage': 21.258,
 'fiftyTwoWeekHigh': 56.72,
 'fiftyTwoWeekLow': 10,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16081769,
 'forwardEps': -3.19,
 'forwardPE': -6.075235,
 'fromCurrency': None,
 'fullTimeEmployees': 89,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01587,
 'heldPercentInstitutions': 1.04787,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/anaptysbio.com',
 'longBusinessSummary': 'AnaptysBio, Inc., a clinical stage biotechnology '
                        'company, engages in developing therapeutic product '
                        'candidates for inflammation and immuno-oncology '
                        "indications. The company's products include Etokimab, "
                        'an anti-interleukin (IL)-33 program for the treatment '
                        'of atopic dermatitis, eosinophilic asthma, and '
                        'chronic rhinosinusitis with nasal polyps; ANB019, an '
                        'anti-IL-36 receptor for generalized pustular '
                        'psoriasis and palmoplantar pustular psoriasis; and '
                        'anti-inflammatory checkpoint modulators for '
                        'inflammatory diseases. It is also developing '
                        'immuno-oncology products, including TSR-042: '
                        'anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, '
                        'and TSR-075: anti-PD-1/LAG-3 bispecific; and '
                        'CC-90006: anti-PD-1 agonist for psoriasis, as well as '
                        'other products for inflammation. AnaptysBio, Inc. has '
                        'an immuno-oncology partnership with TESARO, Inc. and '
                        'TESARO Development, Ltd.; and collaboration with '
                        'Celgene Corporation. The company was formerly known '
                        'as Anaptys Biosciences, Inc. and changed its name to '
                        'AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was '
                        'founded in 2005 and is headquartered in San Diego, '
                        'California.',
 'longName': 'AnaptysBio, Inc.',
 'market': 'us_market',
 'marketCap': 528630176,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_28462113',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -83520000,
 'nextFiscalYearEnd': 1640908800,
 'open': 20.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 362 6295',
 'previousClose': 20.47,
 'priceHint': 2,
 'priceToBook': 1.319714,
 'priceToSalesTrailing12Months': 22.983921,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 20.41,
 'regularMarketDayLow': 19.3,
 'regularMarketOpen': 20.41,
 'regularMarketPreviousClose': 20.47,
 'regularMarketPrice': 20.41,
 'regularMarketVolume': 155965,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27277100,
 'sharesPercentSharesOut': 0.1878,
 'sharesShort': 5123288,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5952179,
 'shortName': 'AnaptysBio, Inc.',
 'shortPercentOfFloat': 0.2883,
 'shortRatio': 11.29,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ANAB',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.081,
 'twoHundredDayAverage': 17.362339,
 'volume': 155965,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.anaptysbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}